Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 52M | 10.5% |
| Gross Profit | 29M | 14% |
| Cost of Revenue | 22M | 6.2% |
| Operating expense | 33M | 2.1% |
| Net Income | 940,000 | 109% |
| EBITDA | -3.3M | 56.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 491M | 1.6% |
| Total Liabilities | 106M | 11.8% |
| Total Equity | 385M | 0.9% |
| Shares Outstanding | 130M | 1.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 13M | 113.1% |
| Cash from investing | -16M | 881.8% |
| Cash from financing | -12M | 606.3% |
EPS
Financial Highlights for Cytek BioSciences in Q3 '24
Cytek BioSciences reported a revenue of 52M, which is a 10.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 29M, marking a 14% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 22M, a 6.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 33M, showing a -2.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 940,000, showing a 109% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -3.3M, showing a 56.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Cytek BioSciences with growth in revenue, gross profit, and net income.
